Oragenics Inc. (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants, following the activation of Royal Adelaide Hospital. The company reported that no serious adverse events have been observed in dosed participants to date and continues to target a Phase IIa data readout in the fourth quarter of 2026.
ONP-002 is a potential first-in-class treatment for concussion and mild traumatic brain injury, delivered through Oragenics’ proprietary intranasal delivery technology. The therapy is designed to target the brain directly via the nasal route, which may offer advantages over systemic administration. The ongoing Phase IIa trial in Australia is evaluating the safety, tolerability, and pharmacokinetics of ONP-002 in patients with mild traumatic brain injury.
In addition to the Australian trial progress, Oragenics announced that it submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company stated that the meeting supports its goal of submitting an Investigational New Drug (IND) application in the fourth quarter of 2026. A Type B meeting is typically sought to discuss specific issues related to a drug development program, such as clinical trial design or regulatory pathway.
The activation of all trial sites and the submission of the FDA meeting request mark significant milestones for Oragenics as it advances ONP-002 toward potential approval. Concussion, or mild traumatic brain injury, is a major public health concern, with millions of cases occurring annually worldwide. Currently, there are no FDA-approved treatments specifically for concussion, highlighting the unmet medical need that ONP-002 aims to address.
Oragenics is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics through its intranasal delivery platform. The company’s lead candidate, ONP-002, is being developed for concussion and mild traumatic brain injury, with the potential to expand into other neurological conditions such as Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. The company’s intranasal delivery technology could provide a non-invasive method to deliver drugs directly to the brain, potentially improving efficacy and reducing systemic side effects.
For investors and stakeholders, the progress of ONP-002 through clinical trials and regulatory interactions is a key indicator of the company’s trajectory. The absence of serious adverse events in the Australian trial is a positive safety signal, while the upcoming FDA meeting will help shape the U.S. development plan. If successful, ONP-002 could become a first-in-class therapy for concussion, offering a new treatment option for patients and potentially capturing a significant market opportunity.
More information about Oragenics and its programs can be found at oragenics.com.
